Preclinical Development – Chemical
2019 PharmSci 360
This Rapid Fire speech presents the design, study and construction of a powder dosage form of flurbiprofen for nose-to-brain delivery, proposed for the management of Alzheimer’s disease (AD) at early stage. The nasal powder exploits a drug delivery platform where flurbiprofen-containing microparticles are agglomerated into coarser soft clusters, free flowing (chimera agglomerates). The powder’s “chimerical structure” is functional to drug dosing and intranasal deposition and is lost when the microparticles are released and dissolve in the mucosal fluid. Plasma pharmacokinetic and brain distribution of flurbiprofen after the powder in vivo administration to rats will be presented.